AstraZeneca Signs a License Agreement with Theragnostics for its PARP Inhibitor

 AstraZeneca Signs a License Agreement with Theragnostics for its PARP Inhibitor

AstraZeneca Signs a License Agreement with Theragnostics for its PARP Inhibitor

Shots:

  • Theragonistics to get intellectual property rights to operate globally in the diagnostic field for selected radio radionuclide labeled PARPi along with an exclusive option to license for operating globally in the therapeutic field of selected rPARPi
  • Theragonistics will develop molecular radiotherapy based on PARP inhibitor through its platform for the diagnosis and treatment of multiple cancer
  • PARP inhibitors are a novel class of cancer therapies act by inhibiting Poly (ADP-Ribose) Polymerase enzyme which is used by cancerous cells to damage DNA both endogenous and as caused by treatments like chemotherapy

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Chicago Tribune

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post